Sofia Merajver as an expert in genetics, prevention, and transitional science, Dr. Merajver envisioned and planned the method of INHERET testing, evaluation, and clinical implementation. Dr. Merajver has published over 287 manuscripts and dozens of chapters in the peer-reviewed literature, and has received numerous honors and awards, and serves on the National Comprehensive Cancer Network devoted to creating guidelines for prevention.
Current role
Co-founder & Chief Scientific Officer at Inato
Co-Founder & Chief Scientific Officer at Praxis Medicines
Co-Founder & Chief Scientific Officer at Earli
Co-Founder & Chief Scientific Officer at Synthace
Co-Founder & Chief Scientific Officer at Co-D Therapeutics